Open access peer-reviewed chapter

Antidiabetic Activities of Terminalia Species in Nigeria

Written By

Franklyn Nonso Iheagwam, Omoremime Elizabeth Dania, Happiness Chijioke Michael-Onuoha, Olubanke Olujoke Ogunlana and Shalom Nwodo Chinedu

Submitted: 15 June 2020 Reviewed: 13 October 2020 Published: 11 December 2020

DOI: 10.5772/intechopen.94474

From the Edited Volume

Alternative Medicine - Update

Edited by Muhammad Akram

Chapter metrics overview

557 Chapter Downloads

View Full Metrics


Terminalia species are well recognised in traditional medicine. They are known for producing fruits and nuts which are edible and possess pharmacotherapeutic properties. They also have ornamental purposes in urban areas where they are found. These species are used by traditional healers in the treatment and management of diabetes mellitus, its complications and other related ailments that are involved in the pathophysiological process of this disease. Research has been extensively done to validate these antidiabetic claims scientifically as well as understand the mechanism and mode of antidiabetic action. This chapter proposes to highlight the antidiabetic activities of Terminalia species found in Nigeria.


  • Terminalia species
  • antidiabetic
  • Nigeria
  • diabetes mellitus
  • mode of action
  • mechanism
  • traditional medicine

1. Introduction

Diabetes mellitus (DM) is a chronic metabolic disorder that is not only affecting various populations worldwide but also poised on affecting the developing nations of the world much more than developed countries [1, 2]. The International Diabetes Foundation (IDF) reported a diagnosis of over 400 million people living with diabetes and postulated an estimated increase to over 600 million people by the year 2040 in a worldwide survey [3, 4]. The report also shows that diabetes accounts for a death every 6 seconds [3]. In a recent study, it was observed that the total reported cases of people affected by DM had increased by 10 million in the subsequent survey carried out by IDF over the next year [5].

DM is a heterogeneous metabolic disorder and is difficult to classify. However, DM has been categorised into three major types based on the pathologic process. Type 1 diabetes mellitus (T1DM), also known as childhood/early-onset diabetes or insulin-dependent DM, is characterised by insulin deficiency as a result of β-cell dysfunction, degeneration and degradation by the immune system [6]. Type 2 diabetes mellitus (T2DM), also known as adult/late-onset diabetes or non-insulin-dependent DM has insulin secretion and insulin resistance (IR) as its major characteristics [7]. Gestational diabetes mellitus (GDM) has glucose intolerance in pregnant women as its major characteristic. It is as a result of the β-cells inability to meet up with the insulin demand in pregnant women without a previous diagnosis of diabetes [8].

Diabetologists have a few other categories, such as tropical DM and Type 3 diabetes mellitus (T3DM). The former is thought to have a relationship with malnutrition [8], while the latter is a suggested mechanistic link to Alzheimer’s disease via inflammatory response and other mechanisms resulting in the pathophysiologic changes relating diabetes to dementia [3]. However, there is little information on the rarer forms of diabetes, such as secondary diabetes, mitochondrial diabetes, maturity-onset diabetes of the young, and latent autoimmune diabetes of adults [9].

1.1 Risk factors

Physical inactivity or sedentary lifestyle, excessive alcohol, overweight, obesity and unhealthy diet intake are modifiable DM risk factors [10]. Family history, hypertension, history of previously impaired glucose tolerance (IGT) or impaired fasting glucose (IFG), advancing age, history of GDM, ethnicity and genetic makeup are some unmodifiable risk factors. However, various researchers have reported that novel risk factors such as short sleep duration [11], noise pollution [12] and environmental toxins [13] contribute to the causal pathways which lead to diabetes. Trade and agricultural production policies are thought to contribute to both individual and societal level risk factors [14].


2. Diabetes mellitus in Nigeria

2.1 Epidemiology

The transition from infectious diseases to non-communicable diseases as leading causes of death is fast becoming a growing epidemiological trend and public health dichotomy in Sub-Saharan African countries [15]. In Africa, there is a 1% estimated prevalence of diabetes in rural areas while in urban areas, the range is from 5–7% [16]. Nigeria accounts for about one-sixth of Africa’s population [1]. The national prevalence of diabetes, which was less than 1% between 1960 and 1990, has risen from 2.2% in 1997 to 5% in 2013 [17]. However, the current prevalence may currently be as high as between 8 and 10% [9], with 4.83% recorded for patients aged 20 and above, accounting for over 3 million people currently living with this condition [18]. This observation makes her the country with the highest number of people living with diabetes and IFG in Africa [19]. Epidemiological statistics show that Nigeria is responsible for one in every five reported sub-Saharan case of diabetes, with a steep increase in the prevalence of this disease from the rural areas to members of the high socio-economic population [9]. Continuous urbanisation, the increasing population and poor economy, will further drive the incidence and burden of diabetes upwards in Nigeria [1, 2, 20]. T2DM appears to be the majority of the DM burden in Nigeria with T1DM accounting for less than 10% of DM cases [21], while tropical DM makes up less than 1% [8]. Lifestyle factors such as sedentary lifestyle, cigarette smoking and generous consumption of alcohol are known risk factors linked to the development of T2DM. Obesity has been reported to be a major contributor to approximately 55% of diagnosed cases of T2DM, with a prevalence of 3.3 to 18% [2]. It has also been associated with several life-threatening diseases such as cardiovascular disease (CVD), several cancer types, as well as reduced quality of life [22, 23]. Diabetes-related morbidity and mortality have been reported to be high in different locations in Nigeria with 105,091 diabetes-related deaths recorded as at 2013 and most patients reported to have been suffering from T2DM [10].

2.2 Management

Given the current DM epidemic and its projected consequences, effective population-based intervention identification has become a priority public health strategy in Sub-Saharan Africa [24]. In Nigeria, insulin, oral glucose-lowering drugs, diet and exercise are used in the management of DM. Complementary and alternative medicine such as concoctions, infusions, tinctures and herbal supplement is also used [1]. Inability to use insulin syringe, the high cost of therapy, few options in the Nigerian market and poor policies on DM management are a few challenges affecting insulin treatment [25]. The medications used in the management of diabetes become less effective over time as most patients do not achieve normal glycaemic control with their use [26], and thus have resulted to possible second-line medications to achieve the normal glycaemic target [27]. Despite the high cost of medication as well as the inability to maintain normal glycaemic control for an extended period, the use of polytherapy to achieve sufficient glucose control is a common feature in Nigeria [28]. Challenges such as needle phobia, hypoglycaemia, drug-associated side effect and cost of medication have made over 46% of diabetic patients opt for complementary and alternative medicine, with Vernonia amygdalina which is also known as “bitter leaf” being most utilised [29]. The school of thought that diabetics should abstain from carbohydrate rich meals has led to the intake of monotonous food like unripe plantain, beans and wheat rich diet [130]. This challenge occurs due to the absence of a taste-appealing standardised diet for diabetics as well as their dietary requirements influenced by economic status, religious and cultural beliefs [1].


3. Terminalia species as medicinal plants

Medicinal plants (MPs) are a rich source of natural products with potential medical interest. There is an increased interest in the use of medicinal plants and their products as a result of their reported wide range application. Asides their application, they are the richest bioresource of modern medicines, nutraceuticals, food supplements, chemical entities for synthetic drugs, pharmaceutical intermediates, folk medicines and drugs of traditional systems of medicine [31]. These plants are also known to contain different plant secondary metabolites such as tannins, flavonoids, saponins alkaloids, terpenoids and phenols, which are responsible for numerous characteristics such as colour, flavour, smell and texture in various parts of these plants. These plant metabolites are also known for their pharmacological mechanism of actions in the treatment, management and prevention of diseases [32].

Terminalia genus has about 250 flowering tree species which belong to the Combretaceae family. They are found in the tropics of Australia, Asia, Africa and South America. The bark of many Terminalia species appear to be cracked from the stem, the branches are arranged in a stepwise manner with the leaves appearing large and leathery on the tips of shoots. The appearance of the leaves is responsible for the genus nomenclature Terminalia which is a derivative of the Latin word Terminus. The fruits of most Terminalia species are edible with deep red, yellow or black pulp colouration and hard nuts [33]. Extensive research has shown that Terminalia species are a rich source of phytocompounds ranging from flavonoids (gallic acid, ellagic acid, quercetin, hesperetin), steroids (β-sitosterol, terminic acid), tannins (punicallin, terchebulin, castalagin), vitamins (α-tocopherol), carotenoids (lutein) and others [33, 34, 35]. The various reported pharmacological activities such as antimalarial, antioxidant, antibacterial, antifungal, cardiovascular effects, antidiarrhoeal, analgesic, anti-inflammatory, hypolipidaemic, hypoglycaemic, antiprotozoal, antiviral, wound healing, antimutagenic and anticancer properties have been attributed to these compounds [33].

3.1 Terminalia species in Nigeria

There are about ten species of Terminalia found in Nigeria, namely; Terminalia altissima (Synonym: superba), Terminalia avicennioides, Terminalia brownii, Terminalia catappa, Terminalia glaucescens, Terminalia ivorensis, Terminalia laxiflora, Terminalia macroptera, Terminalia mollis and Terminalia schimperiana [33, 36, 37]. These species have been reported to be pharmacologically active with antimicrobial, antimycobacterial, wound healing, gastroprotective, antimalarial, antioxidant, antifungal, anthelmintic, antibacterial, antifungal, antiviral, analgesic, radical scavenging, hepatoprotective, anticancer, antimutagenic, antiaging, aldose inhibitory, antiplasmodial, cytotoxic, antipsychotic, sedative, analgesic, anti-inflammatory, trypanocidal, hypolipidaemic, antioxidant, antimycoplasmal and androgenic, properties as shown in Table 1 [34, 35, 38, 39, 40, 41, 42].

Name of specieLocation in AfricaCommon namePharmacological activityReferences
Terminalia altissima (Synonym: superba)Tropical west Africa, Sierra Leone, Congo, Nigeria, CameroonWhite afara, LimbaAntimicrobial, α-glucosidase inhibitory properties[37, 43, 44]
Terminalia avicennioidesWest AfricaKpace, Kpayi, Baushe, IdiAntimycobacterial, wound healing, gastroprotective, antimalarial, antioxidant, antifungal, anthelmentic activities[45, 46]
Terminalia browniiNigeria, Congo, Sudan, Tanzania, Kenya, and Sudano-Sahelian AfricaDifferent names based on locationAntibacterial, antifungal, antiviral activities[47]
Terminalia catappaAfricaIndian almond, Tropical almondAnalgesic, wound healing, antioxidant, radical scavenging, hepatoprotective, anticancer, antimutagenic, antiaging properties[41]
Terminalia glaucescensTropical AfricaDifferent names based on locationAntimicrobial, aldose inhibitory, antiplasmodial, cytotoxic properties[48, 49]
Terminalia ivorensisWestern AfricaIdigbo, Black Afara, BlackbarkAntibacterial, antipsychotic, sedative, analgesic, anti-inflammatory, trypanocidal properties[50, 51]
Terminalia laxifloraSudano-Sahelian AfricaIdi, BausheAntimycoplasmal activitiy[37]
Terminalia macropteraTropical West AfricaOrin idi, kwandareAntimicrobial, antimalarial, hypolipidaemic, antioxidant, antimycoplasmal properties[52, 53]
Terminalia mollisTropical AfricaBush willow, baúshin giíwaáAntimycoplasmal, antimalaria activitiy[33, 54]
Terminalia schimperianaTropical West Africa, Uganda, EthiopiaIdi, Tuit plant, Kwuegh, BuasheAndrogenic, antioxidant, antimicrobial properties[55]

Table 1.

List of Terminalia species found in Nigeria and their reported ethnopharmacological activity.

Terminalia species in Nigeria, have numerous application in the treatment and management of ailments among the various traditional medicine systems of different ethnic groups. Different parts are utilised by traditional healers to treat cholera, malaria, typhoid, hepatitis, stomach ache, tuberculosis, leprosy, diarrhoea, skin diseases, gastritis, hyperglycaemia, diabetes, gonorrhoea, wounds, epilepsy and catarrh [56, 57, 58]. They are also used as tonic, laxative and chewing sticks [26, 59, 60].

Several reports have highlighted some pharmacological properties of Terminalia species in Nigeria, such as its antimicrobial properties, antibacterial property, anti-inflammatory action, anti-HIV, hypoglycaemic, modulatory properties, analgesic, wound healing, antioxidant and radical scavenging activity, hepatoprotective, anticancer, anti-trypanocidal, antimutagenic and antiaging properties.

Nigeria’s vegetation is made up of forests, savannahs and montane land. All others but the latter are further divided into three parts which have ensured the wide distribution of these species across the country. This variation in the country’s vegetation has not only made these Terminalia species specific to Nigeria and West Africa, but accounts for the difference in their evolutionary relationship, development and pharmacologic activity. Upon assessment of the phylogenetic relationship on [61], using the available nucleic acid sequence of the Terminalia species that were deposited in National Center for Biotechnology Information (NCBI) GenBank, it was observed that species that were closely related such as T. catappa and T. glaucescens as well as T. superba and T. avicennioides were located in the same vegetative region of the country (Figure 1). Irrespective of their evolutionary differences, it was observed that there were conserved regions that were similar in the deposited genetic sequence of the Terminalia species in Nigeria showing over 94% sequence similarity (Figure 2).

Figure 1.

Phylogenetic tree of some selected Terminalia species in Nigeria.

Figure 2.

Multiple sequence alignment of some selected Terminalia species in Nigeria.

3.2 Pharmacologic antidiabetic activities of Nigerian Terminalia species

The pharmacologic antidiabetic activity of Terminalia species have been reported in different climes using various in vitro, in vivo and in silico techniques in mice, rat, rabbit and humans to elucidate them. Nonetheless, in Nigeria, there is a paucity of data on the antidiabetic mode of action and mechanisms of Terminalia spp. despite its abundance. However, there are antidiabetic reports of these species from neighbouring countries with similar vegetation.

3.2.1 In vitro assessments

The crude aqueous and hydroethanolic leaf extracts of T. catappa from Nigeria have been reported to inhibit both α-glucosidase and α-amylase effectively. Mixed and non-competitive mode of inhibition were the mechanisms of action elucidated for the extracts [35]. This finding was further corroborated by in silico studies, in which the identified bioactives showed preferential binding to the active site than the allosteric site of α-glucosidase and α-amylase [35]. The α-amylase inhibitory property of crude methanol extract and solvent fractions of T. brownii stem bark was lower than that of acarbose as reported in [62]. When compared with some other medicinal plants, crude ethanol, aqueous and hydroethanolic extracts of T. superba root exhibited better inhibitory action on α-amylase activity than their respective counterparts [63]. For α-glucosidase and lipoxygenase inhibitory activity, the potency of dichloromethane, methanol and solvent fractions of T. macroptera leaves have been established to be more potent than acarbose and quercetin respectively [40].

High-throughput techniques were used to identify isolated bioactive compounds (gallic acid and methyl gallate) from T. superba stem bark dichloromethane extract, which exhibited very high inhibitory property on α-glucosidase activity [64]. Other isolates such as arjunic acid and glaucinoic acid from T. glaucescens stem barks and chebulagic acid, corilagin and narcissin from T. macroptera leaves are reported to exhibit significant β-glucuronidase, α-glucosidase and 15-lipoxygenase inhibitory activity respectively [40, 65].

3.2.2 In vivo assessments

The pre-administration of methanol-methylene chloride extract of T. glaucescens leaves have been reported to confer protective properties in mice against streptozotocin-induced diabetes effects [66]. T. schimperiana root bark extracts have been reported to be effective in reducing blood glucose and excess body lipids in alloxan-induced diabetic rats [67, 68]. The hypoglycaemic activity of T. catappa leaves has also been recorded [69]. The leaves have also been associated with a significant decrease of C-reactive protein, interleukin-6, fibrinogen and inflammatory markers associated with diabetes in rats when compared with other non-steroidal anti-inflammatory drugs [70]. In male rats fed with T. catappa drupe and seeds supplemented-diets for fourteen days, they were found to have exhibited enhanced sexual behaviour and biomarkers relevant to erectile dysfunction that were initially suppressed by streptozotocin-induced diabetic state [71]. Most research on the antidiabetic assessment of Terminalia species in Nigeria have reported the beneficial effect in rats and mice. Interestingly, in Ref. [72], T. catappa intake was found to illicit negative herb-drug effect by increasing the activity of transaminases concomitantly enhancing the adverse hepatic effects of antidiabetic drugs such as pioglitazone and atorvastatin.


4. Conclusion

The Nigerian Terminalia genus is made up of species that possess antidiabetic principles. This activity has been related to the presence and synergistic action of phytochemicals such as tannins, phenolics, terpenoids, flavonoids and other active bioconstituents. The species of this genus in Nigeria can provide great medicinal value to the country and its populace. However, most of the antidiabetic pharmacological assessment has been done only on Terminalia catappa, Terminalia glaucescens and Terminalia schimperiana. Moreso, high throughput analytical techniques and equipment can be utilised to identify and isolate novel phytocompounds that may be of therapeutic value in the management and treatment of diabetes. It is also imperative to identify the sequence of all Nigerian Terminalia species to understand better the genetic relationship, genetic variability, intraspecific variability and traits heritability in vegetative and floral characters of these species.

It was also observed that the majority of antidiabetic assessments of these Terminalia species were done in vitro, in rats and mice. Nonetheless, more in vivo studies should be carried out to identify the molecular mechanisms involved in its antidiabetic activity. Nigeria is the most challenged sub-Saharan nation with diabetes, a public health issue that needs to be tackled urgently. Hence, there is a need to increase translational research and explore the antidiabetic assessment of these Terminalia species directly on patients to extrapolate results that will be beneficial to the Nigerian public health system.



The authors acknowledge Olawumi Toyin Iheagwam for proofreading the manuscript.


Conflict of interest

The authors declare no conflict of interest.


  1. 1. Ogbera AO, Ekpebegh C. Diabetes mellitus in Nigeria: The past, present and future. World Journal of Diabetes. 2014;5(6):905-911
  2. 2. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: A review of current trends. Oman Medical Journal. 2012;27(4):269-273
  3. 3. Boles A, Kandimalla R, Reddy PH. Dynamics of diabetes and obesity: Epidemiological perspective. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2017;1863(5):1026-36.
  4. 4. Pesta DH, Goncalves RLS, Madiraju AK, Strasser B, Sparks LM. Resistance training to improve type 2 diabetes: Working toward a prescription for the future. Nutrition and Metabolism. 2017;14:24
  5. 5. Uloko AE, Musa BM, Ramalan MA, Gezawa ID, Puepet FH, Uloko AT, et al. Prevalence and risk factors for diabetes mellitus in Nigeria: A systematic review and meta-analysis. Diabetes Therapy. 2018;9(3):1307-1316
  6. 6. Enk J, Mandelboim O. The role of natural cytotoxicity receptors in various pathologies: Emphasis on type I diabetes. Frontiers in Immunology. 2014;5:4
  7. 7. Li W, Yuan G, Pan Y, Wang C, Chen H. Network pharmacology studies on the bioactive compounds and action mechanisms of natural products for the treatment of diabetes mellitus: A review. Frontiers in Pharmacology. 2017;8:74
  8. 8. Azevedo M, Alla S. Diabetes in SubSaharan Africa : Kenya, Mali, Mozambique, Nigeria, South Africa and Zambia. International Journal of Diabetes in Developing Countries. 2016;28(4):101-108
  9. 9. Fasanmade OA, Dagogo-Jack S. Diabetes care in Nigeria. Annals of Global Health. 2015;81(6):821-829
  10. 10. Oputa R, Chinenye S. Diabetes in Nigeria – A translational medicine approach. African Journal of Diabetes Medicine. 2015;23(1):7-10
  11. 11. Heianza Y, Kato K, Fujihara K, Tanaka S, Kodama S, Hanyu O, et al. Role of sleep duration as a risk factor for type 2 diabetes among adults of different ages in Japan: The Niigata wellness study. Diabetic Medicine. 2014;31(11):1363-1367
  12. 12. Dzhambov AM. Long-term noise exposure and the risk for type 2 diabetes: A meta-analysis. Noise & Health. 2015;17:23-33
  13. 13. Taylor KW, Novak RF, Anderson HA, Birnbaum LS, Blystone C, DeVito M, et al. Evaluation of the association between persistent organic pollutants (POPs) and diabetes in epidemiological studies: A national toxicology program workshop review. Environmental Health Perspective. 2013;121(7):774-783
  14. 14. Jaacks LM, Siegel KR, Gujral UP, Narayan KMV. Type 2 diabetes: A 21st century epidemic. Best Practice and Research Clinical Endocrinology and Metabolism. 2016;30(3):331-343
  15. 15. Hult M, Tornhammar P, Ueda P, Chima C, Bonamy AE, Ozumba B, et al. Hypertension, diabetes and overweight: Looming legacies of the Biafran famine. PLoS One. 2010;5(10):1-8
  16. 16. Kengne AP, Amoah AGB, Mbanya J. Cardiovascular complications of diabetes mellitus in sub-Saharan Africa. Circulation. 2005;112:3592-3601
  17. 17. International Diabetes Federation. IDF diabetes atlas 2017 [Available from:
  18. 18. Jackson IL, Adibe MO, Okonta MJ, Ukwe CV. Knowledge of self-care among type 2 diabetes patients in two states of Nigeria. Pharmacy Practice. 2014;12(3):1-10
  19. 19. Isara AR, Okundia PO. The burden of hypertension and diabetes mellitus in rural communities in southern Nigeria. Pan African Medical Journal. 2015;20:103-109
  20. 20. Ekwunife OI, Ezenduka CC, Uzoma BE. Evaluating the sensitivity of EQ-5D in a sample of patients with type 2 diabetes mellitus in two tertiary health care facilities in Nigeria. BMC Research Notes. 2016;9:24-28
  21. 21. Muhammad F. Diabetes: A silent killer in Nigeria. Jundishapur Journal of Chronic Disease Care. 2020;9(4):e105702
  22. 22. Akarolo-Anthony SN, Willett WC, Spiegelman D, Adebamowo CA. Obesity epidemic has emerged among Nigerians. BMC Public Health. 2014;14:455-463
  23. 23. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990 – 2010: A systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2224-60.
  24. 24. Oyeyemi AL, Adegoke BO, Oyeyemi AY, Deforche B, De Bourdeaudhuij I, Sallis JF. Environmental factors associated with overweight among adults in Nigeria. International Journal of Behavioral Nutrition and Physical Activity. 2012;9:32
  25. 25. Ogbera AO, Kuku SF. Insulin use, prescription patterns, regimens and costs - a narrative from a developing country. Diabetology and Metabolic Syndrome. 2012;4:50
  26. 26. Kadiri M, Ojewumi A, Agboola D, Adekunle M. Ethnobotanical survey of plants used in the management of diabetes mellitus in Abeokuta, Nigeria. Journal of Drug Delivery and Therapeutics. 2015;5(3):13-23
  27. 27. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;6736(17):1-13
  28. 28. Yusuff KB, Obe O, Joseph BY. Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria. Pharmacy World and Science. 2008;30(6):876-883
  29. 29. Ogbera AO, Dada O, Adeyeye F, Jewo PI. Complementary and alternative medicine use in diabetes mellitus. West African Journal of Medicine. 2010;29:158-162
  30. 30. Udogadi NS, Onyenibe NS, Abdullahi MK. Dietary management of diabetes mellitus with focus on Nigeria. International Journal of Diabetes Research. 2019;2(1):26-32
  31. 31. Ncube NS, Afolayan AJ, Okoh AI. Assessment techniques of antimicrobial properties of natural compounds of plant origin: Current methods and future trends. African Journal of Biotechnology. 2008;7(12):1797-1806
  32. 32. Sarin R. Useful metabolites from plant tissue cultures. Biotechnology. 2005;4(2):79-93
  33. 33. Cock IE. The medicinal properties and phytochemistry of plants of the genus Terminalia (Combretaceae). Inflammopharmacology. 2015;23:203-229
  34. 34. Iheagwam FN, Okeke CO, DeCampos OC, Okere DU, Ogunlana OO, Chinedu SN. Safety evaluation of Terminalia catappa Linn (Combretaceae) aqueous leaf extract: Sub-acute cardio-toxicopathological studies in albino Wistar rats. Journal of Physics: Conference Series. 2019;1299(1):012109
  35. 35. Iheagwam FN, Israel EN, Kayode KO, De Campos OC, Ogunlana OO, Chinedu SN. GC-MS analysis and inhibitory evaluation of Terminalia catappa leaf extracts on major enzymes linked to diabetes. Evidence-based Complementary and Alternative Medicine. 2019;2019:6316231
  36. 36. Idemudia OG. Terpenoids of Nigerian Terminalia species. Phytochemistry. 1970;9(11):2401-2402
  37. 37. Zhang XR, Kaunda JS, Zhu HT, Wang D, Yang CR, Zhang YJ. The genus Terminalia (Combretaceae): An ethnopharmacological, phytochemical and pharmacological review. Natural Products and Bioprospecting. 2019;9(6):357-392
  38. 38. Dwevedi A, Dwivedi R, Sharma YK. Exploration of phytochemicals found in Terminalia sp. and their antiretroviral activities. Pharmacognosy Reviews. 2016;10(20):73-83
  39. 39. Okey E, Madueke A, Ossai E, Anosike A, Ezeanyika L. Anti-diarrhoeal properties of the ethanol extract of Terminalia glaucescens roots on castor oil-induced diarrhoea in wistar rats. Tropical Journal of Natural Products Research. 2020;4(8):446-450
  40. 40. Pham AT, Malterud KE, Paulsen BS, Diallo D, Wangensteen H. α-Glucosidase inhibition, 15-lipoxygenase inhibition, and brine shrimp toxicity of extracts and isolated compounds from Terminalia macroptera leaves. Pharmaceutical Biology. 2014;52(9):1166-1169
  41. 41. Anand AV, Divya N, Kotti PP. An updated review of Terminalia catappa. Phamacognosy Review. 2015;9(18):93-98
  42. 42. Agbedahunsi J, Anao I, Adewunmi C, Croft S. Trypanosidal properties of Terminalia ivorensis a. Chev (Combretaceae). African Journal of Traditional, Complementary and Alternative Medicines. 2006;3(2):51-56
  43. 43. Onyekwelu JC, Stimm B. Terminalia superba. In: Stimm B, Roloff A, Lang UM, Weisgerber H, editors. Enzyklopädie der Holzgewächse: Handbuch und Atlas der Dendrologie: Wiley; 2004. p. 1-12.
  44. 44. Adeyemi FO, Jimoh AA, Wilson UN. A review of mechanical strength properties of some selected timbers in Nigeria. The International Journal of Science and Technoledge. 2016;4(2):9-15
  45. 45. Adewuyi AM, Akangbe YT, Animasaun DA, Durodola FA, Bello OB. Terminalia avicennioides as a potential candidate for pharmaceutical industry: A review. Research Journal of Pharmaceutical Biological and Chemical Sciences. 2015;6(2):748-754
  46. 46. Aliyu H, Suleiman M, Ahmed A, Chiezey N, Ahmed A. Terminalia avicennioides Guill & Perr (Combretaceae): Pharmacology and phytochemistry of an alternative traditional medicine in Nigeria: Mini review. Journal of Pharmacognosy and Natural Products. 2018;4(2):1000152
  47. 47. Salih EY, Julkunen-Tiitto R, Lampi AM, Kanninen M, Luukkanen O, Sipi M, et al. Terminalia laxiflora and Terminalia brownii contain a broad spectrum of antimycobacterial compounds including ellagitannins, ellagic acid derivatives, triterpenes, fatty acids and fatty alcohols. 227, 82-96. Journal of Ethnopharmacology. 2018;227:82-96
  48. 48. Berinyuy BE, Abdullahi M, Kabiru AY, Ogbadoyi EO. Comparative anti-malarial and toxicological properties of the stem bark extracts of Nauclea latifolia and Terminalia glaucescens against plasmodium berghei-infected mice. Iranian Journal of Toxicology. 2020;14(1):9-18
  49. 49. Fahmy NM, Al-Sayed E, Singab AN. Genus Terminalia: A phytochemical and biological review. Medicinal and Aromatic Plants. 2015;4(5):1-22
  50. 50. Chika PJ, Sakpere AM, Akinropo MS. Effect of pretreatments on germination of seeds of the timber plant, Terminalia ivorensis and Mansonnia altissima (a. Chev.). Notulae Scientia Biologicae. 2020;12(2):334-340
  51. 51. Ogunwande IA, Ascrizzi R, Flamini G. Essential oil composition of Terminalia ivorensis a. Chev. Flowers from northern Nigeria. Trends in Phytochemical Research. 2019;3(1):77-82
  52. 52. Haidara M, Haddad M, Denou A, Marti G, Bourgeade-Delmas S, Sanogo R, et al. In vivo validation of anti-malarial activity of crude extracts of Terminalia macroptera, a Malian medicinal plant. Malaria Journal. 2018;17(1):1-10
  53. 53. Usman S, Agunu A, Atunwa S, Hassan S, Sowemimo A, Salawu K. Phytochemical and anti-inflammatory studies of ethanol extract of Terminalia macroptera Guill. & Perr.(Combretaceae) stem bark in rats and mice. Nigerian Journal of Pharmaceutical Research. 2017;13(2):147-156
  54. 54. Muraina IA, Adaudi AO, Mamman M, Kazeem HM, Picard J, McGaw LJ, et al. Antimycoplasmal activity of some plant species from northern Nigeria compared to the currently used therapeutic agent. Pharmaceutical Biology. 2010;48(10):1103-1107
  55. 55. Awotunde OS, Adewoye SO, Dhanabal PS, Hawumba J. Subacute toxicity study of aqueous root extract of Terminalia schimperiana in male Wistar rats. Toxicology Reports. 2019;6:825-832
  56. 56. Khan ME, Bala LM, Maliki M. Phytochemical analyses of Terminalia schimperiana (Combretaceae) root bark extract to isolate stigmasterol. Advanced Journal of Chemistry-Section A (Theoretical, Engineering and Applied Chemistry). 2019;2(4):327-34.
  57. 57. Pham AT, Malterud KE, Paulsen BS, Diallo D, Wangensteen H. DPPH radical scavenging and xanthine oxidase inhibitory activity of Terminalia macroptera leaves. Natural Product Communications. 2011;6(8):1934578X1100600819.
  58. 58. Akinyemi KA. Antibacterial screening of five Nigerian medicinal plants against S. typhi and S. paratyphi. Journal of the Nigerian Infection Control Association. 2000;3(1):30-33
  59. 59. Ezuruike UF, Prieto JM. The use of plants in the traditional management of diabetes in Nigeria: Pharmacological and toxicological considerations. Journal of Ethnopharmacology. 2014;155(2):857-924
  60. 60. Ogundiya MO, Kolapo AL, Okunade MB, Adejumobi JA. Assessment of phytochemical composition and antimicrobial activity of Terminalia glaucescens against some oral pathogens. Electronic Journal of Environmental, Agricultural and Food Chemistry. 2009;8(7):466-471
  61. 61. Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F, et al. robust phylogenetic analysis for the non-specialist. Nucleic Acids Research. 2008;36(W465-W469).
  62. 62. Alema NM, Periasamy G, Sibhat GG, Tekulu GH, Hiben MG. Antidiabetic activity of extracts of Terminalia brownii Fresen. Stem bark in mice. Journal of Experimental Pharmacology. 2020;12:61-71
  63. 63. Momo CEN, Ngwa AF, Dongmo GIF, Oben JE. Antioxidant properties and α-amylase inhibition of Terminalia superba, Albizia sp., Cola nitida, Cola odorata and Harungana madagascarensis used in the management of diabetes in Cameroon. Journal of Health Science. 2009;55(5):732-738
  64. 64. Wansi JD, Lallemand MC, Chiozem DD, Toze FAA, Mbaze LMA, Naharkhan S, et al. α-Glucosidase inhibitory constituents from stem bark of Terminalia superba (Combretaceae). Phytochemistry. 2007;68(15):2096-2100
  65. 65. Rahman AU, Zareen S, Choudhary MI, Akhtar MN, Ngounou FN. Some chemical constituents of Terminalia glaucescens and their enzymes inhibition activity. Zeitschrift für Naturforschung B. 2005;60(3):347-350
  66. 66. Njomen GB, Kamgang R, Soua PR, Oyono JL, Njikam N. Protective effect of methanol-methylene chloride extract of Terminalia glaucescens leaves on streptozotocin-induced diabetes in mice. Tropical Journal of Pharmaceutical Research. 2009;8(1):19-26
  67. 67. Khan M, Bala L, Igoli J. Isolation of caccigenin and investigation of anti-diabetic properties of tropical almond (Terminalia schimperiana) root bark extracts on albino rats. Journal of Chemical Society of Nigeria. 2019;44(3).
  68. 68. Ojewumi A, Kadiri M. Phytochemical screening and anti-diabetic properties of Terminalia schimperiana leaves on rats. International Journal of Green and Herbal Chemistry. 2014;3(4):1679-1689
  69. 69. Koffi NG, Yvetten FN, Noel ZG. Effect of aqueous extract of Terminalia catappa leaves on the glycaemia of rabbits. Journal of Applied Pharmaceutical Science. 2011;1(8):59-64
  70. 70. Ben EE, Asuquo AE, Owu DU. Comparative effect of aspirin, meloxicam and Terminalia catappa leaf extract on serum levels of some inflammatory markers in alloxan induced diabetic rats. Asian Journal of Research in Biochemistry. 2019;4(1):1-10
  71. 71. Adebayo AA, Oboh G, Ademosun AO. Almond-supplemented diet improves sexual functions beyond Phosphodiesterase-5 inhibition in diabetic male rats. Heliyon. 2019;5(12):e03035
  72. 72. Ezuruike U, Prieto JM. Assessment of potential herb-drug interactions among Nigerian adults with type-2 diabetes. Frontiers in Pharmacology. 2016;7:248

Written By

Franklyn Nonso Iheagwam, Omoremime Elizabeth Dania, Happiness Chijioke Michael-Onuoha, Olubanke Olujoke Ogunlana and Shalom Nwodo Chinedu

Submitted: 15 June 2020 Reviewed: 13 October 2020 Published: 11 December 2020